or Try an Advanced Search...

    Technical Analysis for ALXO - ALX Oncology Holdings Inc.

    Grade Last Price % Change Price Change
    F 2.16 2.86% 0.06
    ALXO closed up 2.86 percent on Tuesday, September 10, 2024, on 52 percent of normal volume.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Down Down Down
    Historical ALXO trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness 2.86%
    Wide Bands Range Expansion 2.86%
    Lower Bollinger Band Touch Weakness 2.86%
    Oversold Stochastic Weakness 2.86%
    New 52 Week Closing Low Bearish 13.09%
    Narrow Range Bar Range Contraction 13.09%
    Lower Bollinger Band Walk Weakness 13.09%
    Older End-of-Day Signals for ALXO ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 22 hours ago
    Down 3% about 22 hours ago
    Down 2 % about 22 hours ago
    10 DMA Resistance about 23 hours ago
    Up 3% about 23 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ALXO Chart by TradingView
    Basic chart:

    Profile

    ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Oncology Cancer Immunotherapy Acute Myeloid Leukemia Epidermal Growth Factor Receptor Carcinoma Myelodysplastic Syndrome Syndromes Treatment Of Myelodysplastic Syndrome

    Is ALXO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 9 ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
    Sep 4 ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
    Aug 27 Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
    Aug 9 ALX Oncology GAAP EPS of -$0.76 in-line
    Aug 8 ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    Aug 6 ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
    Aug 1 Dow Dips Over 500 Points; ISM Manufacturing PMI Falls In July
    Aug 1 Immuno-Oncology Focused ALX Oncology Stock Falls On Updated Data From Mid-Stage Evorpacept Combo Study In Gastric Cancer Patients
    Aug 1 ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial
    Jul 31 ALX Oncology reports Phase 2 data for gastric cancer drug evorpacept
    See more ALXO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.825
    52 Week Low 1.88
    Average Volume 1,368,301
    200-Day Moving Average 10.71
    50-Day Moving Average 4.18
    20-Day Moving Average 2.35
    10-Day Moving Average 2.18
    Average True Range 0.28
    RSI (14) 31.51
    ADX 51.52
    +DI 12.08
    -DI 31.59
    Chandelier Exit (Long, 3 ATRs) 1.95
    Chandelier Exit (Short, 3 ATRs) 2.72
    Upper Bollinger Bands 2.80
    Lower Bollinger Band 1.91
    Percent B (%b) 0.28
    BandWidth 37.84
    MACD Line -0.59
    MACD Signal Line -0.71
    MACD Histogram 0.1229
    Fundamentals Value
    Market Cap 107.61 Million
    Num Shares 49.8 Million
    EPS -3.57
    Price-to-Earnings (P/E) Ratio -0.61
    Price-to-Sales 5906.24
    Price-to-Book 4.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.43
    Resistance 3 (R3) 2.41 2.30 2.39
    Resistance 2 (R2) 2.30 2.23 2.31 2.37
    Resistance 1 (R1) 2.23 2.19 2.27 2.25 2.35
    Pivot Point 2.12 2.12 2.14 2.13 2.12
    Support 1 (S1) 2.05 2.05 2.09 2.07 1.97
    Support 2 (S2) 1.94 2.01 1.95 1.95
    Support 3 (S3) 1.87 1.94 1.94
    Support 4 (S4) 1.89